Purified component of blue-green algae and method of use

1. A method of mobilizing hematopoietic stem cells in a subject, comprising:

administering to the subject a therapeutically effective amount of a composition, thereby mobilizing hematopoietic stem cells in the subject,

wherein the composition comprises a first and a second component of Aphanizomenon fibs aquae , wherein the first component consists of a dried form of a solvent extract of fresh, dehydrated, or preserved Aphanizomenon fibs aquae , wherein the extract comprises a selectin ligand that binds specifically to L-selectin, and inhibits fucoidan-mediated expression of the CXCR4 receptor, and the solvent consists of water or buffered saline; and wherein the second component consists of a dried form of a second solvent extract of fresh, dehydrated, or preserved Aphanizomenon flos aquae , wherein the second solvent comprises ethanol.

2. The method of claim 1 , wherein the second solvent extract is produced by suspending dried Aphanizomenon flos aquae in about 10 to about 20 percent ethanol at about 50° C. to about 60° C.

3. The method of claim 1 , wherein the composition comprises about 1 gram to about 2 grams of the first component of Aphanizomenon flos aquae , and about 100 milligrams to about 500 milligrams of the second component of Aphanizomenon flos aquae.

4. The method of claim 1 , wherein the composition comprises about 1 gram of the first component of Aphanizomenon flos aquae , and about 150 milligrams of the second component of Aphanizomenon fibs aquae.

5. The method of claim 1 , wherein the composition is produced by the process of

contacting a first amount of Aphanizomenon flos aquae in a solvent consisting of water or phosphate buffered saline for about half an hour to about 12 hours to produce a first solvent extract;

removing solid material from the first solvent extract;

drying the first solvent extract to produce a solid composition comprising a L-selectin ligand;

incubating a second amount of Aphanizomenon flos aquae in 10 percent ethanol at about 50° C. for about one hour to produce a second solvent extract;

removing solid material from the second solvent extract;

drying the second solvent extract to produce a solid form of the second solvent extract; and

mixing a therapeutically effective amount of the solid composition comprising the L-selectin ligand and a therapeutically effective amount of the solid form of the second solvent extract.

6. The method of claim 1 , wherein the hematopoietic stem cells express CD34, CD133, or both.

7. The method of claim 6 , further comprising measuring the number of CD34+ stem cells in a sample from the subject.

8. The method of claim 1 , wherein the subject is a human subject.

9. The method of claim 1 , wherein the subject is healthy.

10. The method of claim 1 , wherein the subject has a chronic illness, traumatic injury, osteoporosis, Alzheimer's disease, cardiac infarction, Parkinson's disease, traumatic brain injury, multiple sclerosis, cirrhosis of the liver, a digestive system disorder, a nervous system disorder, a lymph system disorder, a cardiovascular system disorder, an endocrine system disorder, a degenerative disease or is immunosuppressed.

11. The method of claim 1 , wherein stem cell homing is increased about 100% to about 500% in the subject as compared to a control.

12. A method of mobilizing hematopoietic stem cells in a subject, comprising:

administering to the subject a therapeutically effective amount of a composition, thereby mobilizing hematopoietic stem cells in the subject,

wherein the composition comprises about 1 gram of a first component of Aphanizomenon flos aquae and about 150 milligrams of a second component of Aphanizomenon flos aquae , wherein the first component consists of a dried form of a first solvent extract of fresh, dehydrated, or preserved Aphanizomenon flos aquae , wherein the first solvent extract comprises a L-selectin ligand that binds specifically to L-selectin and inhibits fucoidan-mediated expression of the CXCR4 receptor, and wherein the first solvent consists of water or buffered saline; and wherein the second component consists of a dried form of a second solvent extract of fresh, dehydrated, or preserved Aphanizomenon flos aquae , wherein the second solvent comprises about 10 percent to about 20 percent ethanol.

13. The method of claim 12 , wherein the first solvent consists of water.

14. The method of claim 12 , wherein the first solvent consists of buffered saline.

15. The method of claim 12 , wherein the second solvent comprises about 10 percent ethanol.

16. The method of claim 12 , wherein the second solvent comprises about 20 percent ethanol.

17. The method of claim 12 , wherein the composition is in a solid or a liquid form.

18. The method of claim 17 , wherein the composition is a solid, and wherein the solid is encapsulated.

19. The method of claim 12 , wherein the hematopoietic stem cells express CD34, CD133, or both.

20. The method of claim 19 , further comprising measuring the number of CD34+ stem cells in a sample from the subject.

21. The method of claim 12 , wherein the subject is human subject.

22. The method of claim 12 , wherein the subject is healthy.

23. The method of claim 12 , wherein the subject has a chronic illness, traumatic injury, osteoporosis, Alzheimer's disease, cardiac infarction, Parkinson's disease, traumatic brain injury, multiple sclerosis, cirrhosis of the liver, a digestive system disorder, a nervous system disorder, a lymph system disorder, a cardiovascular system disorder, an endocrine system disorder, a degenerative disease or is immunosuppressed.

24. The method of claim 12 , wherein stem cell homing is increased about 100% to about 500% in the subject as compared to a control.